Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2019 Financial Results
February 19, 2020 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals to Present at the 2020 BIO CEO & Investor Conference
February 03, 2020 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals Reviews 2019 Achievements and Announces Key Business Objectives for 2020
January 13, 2020 07:00 ET
|
Cyclacel
– Anticancer Activity of CYC065 Monotherapy in Patients with MCL1 Amplified Solid Tumors and CYC065-venetoclax combination in AML/MDS and CLL dose escalation studies – BERKELEY HEIGHTS, N.J., Jan. ...
Cyclacel Pharmaceuticals to Present at Biotech Showcase™ 2020 in San Francisco
January 06, 2020 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel’s CYC065 and Venetoclax Demonstrate Therapeutic Potential and Anticancer Activity in Acute Myeloid and Chronic Lymphocytic Leukemias
December 09, 2019 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing...
Cyclacel Pharmaceuticals Reports Third Quarter 2019 Financial Results
November 13, 2019 16:05 ET
|
Cyclacel
– Investigator-Reported Partial Response in Phase 1 Study of CYC065 as Single Agent – – Conference Call Scheduled November 13, 2019 at 4:30 p.m. ET – BERKELEY HEIGHTS, N.J., Nov. 13, 2019 (GLOBE...
Cyclacel Pharmaceuticals Announces Multiple Clinical Abstracts Selected for Presentation at the ASH 2019 Annual Meeting
November 06, 2019 09:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference
September 23, 2019 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...
Cyclacel Pharmaceuticals Announces First Patient Treated With Oral CYC065 in a Phase 1 Study in Patients With Advanced Solid Tumors
September 09, 2019 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals Reports Second Quarter 2019 Financial Results
August 13, 2019 16:05 ET
|
Cyclacel
- Conference Call Scheduled August 13, 2019 at 4:30 p.m. ET – BERKELEY HEIGHTS, N.J., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or...